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ABSTRACT 
Background: High intra-hepatic fat (IHF) content is associated with insulin resistance, 
visceral adiposity, and increased morbidity and mortality following liver resection. However, 
in clinical practice, IHF is assessed indirectly by pre-operative imaging [for example, 
chemical-shift magnetic resonance (CS-MR)]. We used the opportunity in patients 
undergoing liver resection to quantify IHF by digital histology (D-IHF) and relate this to CT-
derived anthropometrics, insulin-related serum biomarkers, and IHF estimated by CS-MR. 
Methods:  A reproducible method for quantification of D-IHF using 7 histology slides (inter- 
and intra-rater concordance: 0.97 and 0.98) was developed. In 35 patients undergoing 
resection for colorectal cancer metastases, we measured: CT-derived subcutaneous and 
visceral adipose tissue volumes, Homeostasis Model Assessment of Insulin Resistance 
(HOMA-IR), fasting serum adiponectin, leptin and fetuin-A. We estimated relative IHF using 
CS-MR and developed prediction models for IHF using a factor-clustered approach. 
Results: The multivariate linear regression models showed that D-IHF was best predicted 
by HOMA-IR (Beta coefficientper doubling: 2.410, 95% CI: 1.093, 5.313) and adiponectin (βper 
doubling: 0.197, 95% CI: 0.058, 0.667), but not by anthropometrics. MR-derived IHF correlated 
with D-IHF (rho: 0.626; p = 0.0001), but levels of agreement deviated in upper range values 
(CS-MR over-estimated IHF: regression versus zero, p = 0.009); this could be adjusted for 
by a correction factor (CF: 0.7816). 
Conclusions: Our findings show IHF is associated with measures of insulin resistance, but 
not measures of visceral adiposity. CS-MR over-estimated IHF in the upper range. Larger 
studies are indicated to test whether a correction of imaging-derived IHF estimates is valid. 
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INTRODUCTION 
Excess intra-hepatic fat (IHF), commonly termed steatosis, is present in approximately one 
third of patients with colorectal liver metastases (CLM).1-3 Moderate to severe steatosis 
(triglyceride content >33%4) and steatohepatitis (steatosis with hepatocyte ballooning, 
lobular inflammation and fibrosis4) are associated with increased post-operative morbidity 
(two-fold increase) and peri-operative mortality (2.8- to 10-fold increase).5, 6 Retrospective 
studies have shown excess body mass index (BMI), diabetes and pre-operative 
chemotherapy are associated with steatosis and/or steatohepatitis in the resection 
specimen.3, 5, 7 
Within the general population, visceral adipose tissue (VAT) but not subcutaneous 
adipose tissue (SAT), correlates with intra-heaptic fat (IHF).8-10 Consistent with this, serum 
surrogate biomarkers of insulin resistance independently predict for IHF.9-11 However, IHF is 
determined indirectly by non-invasive imaging modalities, either using ultrasound scans in 
large cohorts,12 or in clinical practice, by pre-operative chemical-shift MR (CS-MR).13 
Magnetic resonance (MR) spectroscopy may offer greater performance characteristics but 
its utility is limited to the research setting.14, 15 
To directly inform the above relationships, and pre-operative assessment, we used 
the opportunity in patients undergoing liver resection, to quantify IHF by digital histological 
assessment (D-IHF) and related this with CT-derived anthropometrics (VAT and SAT), 
insulin-related serum biomarkers, and IHF estimated by CS-MR. 
  
METHODS 
Patients  
The study schema is outlined in (Figure 1). Patients planned for resection of colorectal liver 
metastases (CLM) at North Manchester General Hospital, Manchester, United Kingdom, 
were prospectively recruited between January 2012 and June 2013; all gave informed 
consent. All patients underwent pre-operative CT, CT-PET and CS-MR imaging as routine 
clinical care; the decision to proceed to resection was made at a multidisciplinary team 
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meeting.16 Individuals who were recruited but did not undergo resection were still included if 
an intra-operative biopsy that included background liver was performed. We excluded 
patients undergoing re-do resections (where the regenerated liver is likely to be 
unrepresentative) and patients treated with more than one line of pre-operative 
chemotherapy (where there may be increased risk of chemotherapy-induced liver injury 
and/or cancer-related weight loss). Pre-operative chemotherapy was defined as any 
chemotherapy administered within the six-month period preceding liver resection (the 
definition used in a recent National Clinical Research Network Trial).17 Data on 
complications, pre-operative liver enzymes levels and length of hospital were collected. 
Height, weight (to derive BMI), waist circumference (WC) and hip circumference (to 
derive waist-to-hip ratio [WHR]) were measured before surgery. Waist circumference was 
measured at the level of the anterior superior iliac spines; hip circumference at the gluteal 
level.7  
 
Development of digital histology quantification of intra-hepatic fat (D-IHF) 
Seven digital images of routine H&E slides of the background liver were taken by a single 
consultant hepatobiliary pathologist (MaRa) at x10 magnification and maximum resolution. 
Each photograph was imported into Adobe Photoshop and converted to a greyscale image; 
the levels were then adjusted to increase the contrast. The image was magnified and the 
magic wand tool used to capture areas of fat deposition, leaving behind normal parenchyma. 
The D-IHF percentage was determined by counting the number of highlighted pixels divided 
by the total number using the histogram tool. Individual percentages were recorded and a 
mean value was derived for each patient from the 7 digital images. Seven slides were 
chosen based on a previous digital morphometry study reporting minimal intra- and inter-
observer variability for 7 slides.18  
The validity of this new 7-slide technique was tested by examining 43 images in one 
patient. The mean digitally quantified histological score from the 43 images was 4.30. We 
randomly sampled this data with replacement as samples n = 40, n = 35, n = 30….. n = 4 
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(see supplemental material). Each re-sampling was performed 500 times. For each number 
of slides, a distribution (n = 500) of means was derived, with a mean and 5th and 95th 
percentiles. Setting the limits of acceptable variation between +25% and -25% of the true 
mean (i.e. 3.23 and 5.38) the probability that the derived mean lay outside the pre-set limits 
was high if we examined less than 7 slides. Inter- and intra-rater variability for the 7-slide 
technique was minimal – Concordance Correlation Coefficients [CCC]: 0.97 and 0.98, 
respectively. Standard visual estimations of steatosis grade according to Kleiner-Brunt 
criteria4 were also performed. 
 
CT-derived VAT and SAT volumes 
Pre-operative CT scans were analyzed using OsiriX software to determine SAT and VAT 
areas and volumes. To measure SAT area, a mean +/- 2 standard deviation fat attenuation 
value was derived by drawing regions of interest (ROIs) in the subcutaneous fat 
compartment at the level of the right renal hilum. A narrow fat attenuation window specific to 
each patient avoided areas of connective tissue, fibrosis and vessels. The edge of the 
peritoneal cavity was traced to leave behind only subcutaneous fat and the Grow Region 2D 
tool used to input upper and lower thresholds for fat attenuation. The same technique was 
used for VAT area, drawing an ROI in the visceral fat and subtracting the SAT. Any fat deep 
to the rectus sheath and outer edge of para-spinal muscles, including inter-muscular fat 
between quadratus lumborum and erector spinae was included in the visceral fat 
compartment.  
To account for changes in SAT and VAT compartments at different vertebral levels19 
we derived SAT and VAT volumes. A 120mm section running cranially from the L5-S1 disc 
was used with the Grow Region 3D tool to derive volumes from individual areas. Each CT 
parameter was measured twice to assess intra-rater variability; measurements were 
repeated by an independent observer (AAP) to explore inter-rater variability (see 
supplemental material).  There was good to excellent agreement for all measurements 
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(range of CCCs: 0.86-0.99). In general, inter-rater variability was greater than intra-rater 
variability.  
 
Serum biomarkers of insulin resistance 
Pre-surgery fasting (at least 4 hours) plasma levels of glucose and serum insulin, 
adiponectin, leptin and fetuin-A were determined following blood collection in standard 
serum tubes and centrifuged at 3,000rpm for 15min at 5°C. Serum (3-5mls) was stored at -
80°C before transfer for analysis at the Medical Re search Laboratory, University of Aarhus, 
Denmark. The assay techniques have been described elsewhere.20 Briefly, glucose 
concentrations were analyzed by the glucose oxidase method, Beckman Instruments, CA, 
USA; insulin by a two-site immunospecific Enzyme-Linked ImmunoSorbent Assay (ELISA), 
Dako, Denmark; adiponectin by an in-house Time-Resolved ImmunoFluoroMetric Assay 
(TR-IFMA) based on two monoclonal antibodies and recombinant human adiponectin (R&D 
Systems, Abingdon, UK); leptin by a validated in-house TR-IFMA based on two commercial 
monoclonal antibodies and commercial recombinant human leptin as the standard, R&D 
Systems, Abingdon, UK. Fetuin-A levels were determined by a commercial Quantikine 
ELISA from R&D Systems in accordance with instructions from the manufacturer. To 
estimate insulin resistance, we derived a HOmeostasis Model Assessment of Insulin 
Resistance (HOMA-IR) value for each patient.21 HOMA-IR has good correlation with the 
euglycaemic clamp (r = 0.88) and has been validated in healthy subjects.22 
 
Relative hepatic fat content on chemical shift MR imaging 
Relative IHF content was determined from pre-operative CS-MR scans, and cross-checked 
against D-IHF. We measured In- and Out- signal intensity in three 1.5-2cm2 Regions of 
Interest (ROI) in liver segments II, V and VIII using a PACS (Picture Archiving and 
Communication System) workstation. ROI intensity was derived using the standard formula ( 
[In-Out] / [2In]).23 Each ROI was placed distant from major vessels, ducts and tumour 
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following consensus between the same two observers (EP and PM). Where it was not 
possible to use segments II, V and VIII, the nearest suitable segment was chosen. 
 
Statistical analyses 
All analyses were performed using Stata, version 12.1, (College Station, TX, USA). Standard 
approaches to categorical (chi-squared test) and continuous (Mann-Whitney U test) 
variables were used. Correlation matrices were constructed to assess relationships between 
D-IHF and other continuous variables using Spearman’s Rank Correlation Coefficient. To 
account for multiple testing, a p-value of <0.01 was considered to indicate statistical 
significance.  
Predictors of intra-hepatic fat content were explored using multivariable linear 
regression models. To reduce the right skewness of the distributions of some insulin-related 
biomarkers, the base 2 logarithmic transformation was used, which leads to a convenient 
interpretation: the beta coefficient associated with a change of one unit on the log2 scale 
corresponds to the slope associated with a doubling in biomarker level on the original scale. 
Because of the large number of variables and the anticipated high levels of correlations, we 
used a factor-cluster method as shown in Figure S3 (supplemental material). There were 
four clusters – patient-related; anthropometric measures; CT-derived anthropometrics; and 
insulin-related serum biomarkers. A separate model was developed for each cluster and 
significant (p < 0.05) variables selected for the final model. Model fit was assessed using the 
Akaike Information Criterion (AIC), Stata command: fitstat.24 AIC takes in to account 
degrees of freedom – a lower value indicates a better fit.  
Using a 1,000-patient replacement simulation model, predicted values for median 
digital fat percentage of 10% and BMI of 25 kg/m2 (standard deviation: 5 kg/m2) in a 
hypothetical cohort, it was estimated that 30 patients would be required to detect a 
significant (p < 0.05) Spearman correlation (probability = 96%, CIs: 79-100%).  
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RESULTS 
Baseline characteristics 
Thirty-seven patients were recruited but following exploratory laparotomy: 4 patients did not 
proceed to resection, of which open biopsies were taken in two. Thus, there were 35 
patients eligible for D-IHF quantification.(median age 64 years, 20 males, 15 treated with 
pre-operative chemotherapy, see Table 1). 
Gender-specific differences were observed across anthropometric measurements, 
such as men having significantly higher WC (107 cm versus 103 cm, p = 0.037) and VAT 
volume (1833 cm3 versus 1001 cm3, p = 0.003). There were also differences for insulin-
related biomarkers: men had lower median leptin levels (men versus women: 13.0 µg/l 
versus 21.8 µg/l, p = 0.020) and lower median adiponectin levels (11.8 mg/l versus 16.2 
mg/l, p = 0.013).  
The median D-IHF percentage was 1.13% (range: 0% to 9.78%). Independent visual 
estimations of histology grade by the pathologist classified 8 cases as normal, 11 as mild 
steatosis, 5 cases as moderate, 1 as mild steatosis with sinusoidal congestion, 2 as 
sinusoidal congestion and 8 as non-specific inflammation/hepatitis. The median fat 
percentage for the 5 cases of visually estimated moderate grade steatosis was 6.89% 
(range: 4.65% to 9.09%). There was no difference in liver fat percentage by gender, 
diabetes status and whether or not pre-operative chemotherapy was administered. There 
was no association between D-IHF and post-operative complications (grade 3 and 4), liver 
function tests or length of hospital stay. 
 
Correlation analysis 
Results for the correlation analysis are displayed in Table 2. In general, pre-operative 
anthropometrics were strongly correlated with each other (for example, BMI and WC, rho: 
0.786) and with the CT measurements (SAT volume and BMI, rho: 0.752). HOMA-IR was 
correlated with general anthropometrics (all rho > 0.5) but relationships with individual 
visceral fat compartments were weaker (for example, VAT volume and HOMA-IR, rho: 
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0.384). Leptin correlated with BMI, HOMA-IR, and measures of subcutaneous fat, but not 
visceral fat; adiponectin levels were inversely related to measures of body fat. WC and VAT 
volume were moderately correlated with D-IHF (rho: 0.349, p = 0.040; and 0.359, p = 0.034, 
respectively).  
 
Predicting intra-hepatic fat content  
Multivariate linear regression models were built with D-IHF as the dependent factor and the 
following factor clusters: (i) patient-related factors; (ii) anthropometrics; (iii) CT-derived 
measures of adiposity; and (iv) insulin-related serum biomarkers. Using a stepwise 
approach, we selected candidates for the preliminary model, and ultimately the final model, 
assessing model fit with AIC values at each step. Age and gender were included in all 
models. The final model, containing age, gender, weekly alcohol consumption, HOMA-IR 
and adiponectin is shown in Table 3. The multivariate linear regression models showed that 
D-IHF was best predicted by HOMA-IR (Beta coefficientper doubling: 2.41, 95% CI: 1.093, 5.313) 
and adiponectin (βper doubling: 0.197, 95% CI: 0.058, 0.667), but not by anthropometric 
measures of visceral adiposity. 
 
Level of agreement between MR relative IHF and D-IHF  
We tested the relation between In-Out intensity (signal fat fraction) and D-IHF. There was a 
moderate correlation between the In-Out phase ratio on pre-operative CS-MR and D-IHF 
(rho: 0.626, P = 0.0001) (Figure 2a). Levels of agreement were explored using Bland-
Altman plots. There was a trend for MR-derived relative IHF to overestimate IHF content 
relative to D-IHF, especially in upper range values (regression versus zero, p = 0.009) 
(Figure 2b). Restricting the regression to a (0,0) intercept (i.e. no constant), the correction 
factor (CF) was 0.7816. This predicted model for CS-MR values gives a regression 
coefficient with D-IHF of 0.999. 
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DISCUSSION 
Main findings 
This study uniquely quantified IHF directly based on a reproducible digital histology 
quantification method using images from multiple sections through the liver. Our findings 
support the hypothesis that IHF is strongly associated with measures of insulin resistance, 
such as HOMA-IR and adiponectin (inversely), but not anthropometric measures of visceral 
adiposity. We additionally demonstrated that MR chemical-shift relative quantification may 
overestimate IHF content, but this can be corrected for. Larger studies are indicated to test 
whether a correction of imaging-derived IHF estimates are valid. 
 
Comparison with published literature 
Gender-specific differences for anthropometrics and serum biomarkers of insulin resistance 
(for example, increased VAT in men), have been reported previously within the metabolic 
literature,8, 9, 25 as have the relationships we observed between individual anthropometrics, 
CT-measurements and serum biomarkers (for example, leptin correlating with subcutaneous 
but not visceral fat).11, 26 The principle finding in this study – that IHF is significantly 
associated with measures of insulin resistance rather than physical measures of body and 
visceral fat – has also been described previously, but only where IHF content was quantified 
indirectly using MR spectroscopy.9, 27  
Previous studies exploring predictors of excess IHF in liver resection cohorts were 
retrospective and relied upon data captured as part of routine clinical assessment and visual 
assessment of liver histology, however, both excess BMI and diabetes were consistent 
predictors of steatosis and/or steatohepatitis.7, 28 Our finding that the median digital intra-
hepatic fat percentage was 6.89% for the 5 cases graded as “moderate steatosis” by the 
pathologist (triglyceride content >33% by Kleiner-Brunt criteria4) is consistent with those of 
previous studies reporting visual estimations of steatosis grade or percentage to be at least 
4 times higher than digital histological or biochemical measurements.18, 29 
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Clinical implications 
It appears from this study that steatosis and steatohepatitis in liver surgery patients share 
aetiologies common to those seen in non-alcoholic fatty liver disease (NAFLD). Therefore, 
strategies that reduce IHF in NAFLD may be effective in surgical patients as well. For 
example, significant reductions in hepatic triglyceride content (in excess of 50%) can be 
achieved within a few days of starting a low-carbohydrate diet.30, 31 Thus, using MR imaging 
to indirectly quantify IHF content, it may be possible to identify “high risk” patients pre-
operatively and initiate a low-carbohydrate diet to reduce the chances of post-resection 
mortality. The next platform of studies should test the reliability and reproducibility of intra-
hepatic fat measurement in CLM patients using non-invasive imaging and quantify 
reductions in triglyceride content following dietary intervention. 
 
Strengths and limitations 
There are several strengths to this study. First, the data was collected prospectively before 
liver resection surgery. Previous studies have been retrospective5, 7, 28 limiting variables 
examined to those routinely captured within an institution’s database, such as BMI. Second, 
this was a homogenous patient group because we excluded re-do resections (to avoid 
sampling a regenerated liver not exposed to a lifetime of risk factors for steatosis) and 
patients treated with multiple lines of pre-operative chemotherapy (where there may be 
increased risk of chemotherapy-induced liver injury and/or cancer-related weight loss). Third, 
we developed a reliable and reproducible method of intra-hepatic fat quantification; previous 
studies5-7, 28 have relied upon visual estimations of steatosis grade or percentage, which are 
not reproducible32 and overestimate the fat percentage.18, 29 Fourth, we explored for novel 
predictors such as VAT volume, HOMA-IR, adiponectin and fetuin-A – parameters not 
previously examined in the surgical population. 
A limitation of this study is the relatively small sample size. However, we attempted 
to compensate for this by characterizing a deep phenotype for each patient, using multiple 
measures of adiposity and insulin resistance. A further limitation is the cross-sectional 
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design, with the denominator (D-IHF) captured at the time of liver resection surgery only. 
Measuring liver fat content at different time points during treatment and exploring how it may 
alter in relation to changes in body fat distribution and/or insulin resistance would have been 
informative, however, findings from this exploratory work set a platform for the next 
generation of studies.   
 
Future research 
There are two key unanswered questions. First, is it feasible to identify patients with 
moderate/severe steatosis or steatohepatitis before surgery and reduce intra-hepatic fat 
content? And second, if it is, will this translate into improved peri-operative outcome? In the 
study by Vauthey et al 5 reporting an increase in peri-operative mortality for steatohepatitis, 
the interval between finishing chemotherapy and liver resection was less than 6 weeks. In 
subsequent studies, the chemotherapy to surgery interval has been longer,7, 28 which may 
reflect a wider change in practice across other hepatobiliary units. Given the projected 
increase in the numbers of patients eligible for resection of CLM, and a parallel increase in 
the prevalence of steatosis in Western populations, better understanding of this topic is likely 
to benefit many patients. 
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Figure 1. Study design. Upper panel: Pre-operative CT scans were analyzed using OsiriX 
software to determine subcutaneous (SAT) and visceral adipose tissue (VAT) areas and 
volumes (indicated by yellow arrows). Lower panel: Digital quantification with Adobe 
Photoshop. Areas of fat are highlighted using the magic wand; the size of the highlighted 
area is recorded as a pixel count  
 
Figure 2 (a) Scatter plot of digital fat percentage (loge scale) versus In-Out signal intensity 
ratio on the clinical pre-operative MR scans for the 35 patients with available histology. (b) 
Bland-Altman plots of D-IHF versus relative IHF determined by chemical-shift MR imaging.  
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Table 1 Pre-operative characteristics, n = 35 
 
   
Median age at hepatectomy (years) 64 (38-80) 
Gender 
 
 Men 20 
Women 15 
ASA Grade 
 
 I 8 
II 23 
III-IV 4 
Diabetes 
 
 Yes 6 
No 29 
BMI (kg/m2) 
 
 Underweight (<18.5) 1 
Normal weight (18.5-24.9) 9 
Overweight (25.0-29.9) 16 
Obese (≥30.0) 9 
Site of primary tumour 
 
 Colon 13 
Rectum 22 
Dukes’ stage of primary tumour 
 
 A 1 
B 9 
C 19 
Complete pathological response 1 
Synchronous resection 3 
Liver first, primary in-situ 2 
Pre-operative CEA level – median (IQR) (ng/ml) 5 (2 -27) 
Pre-operative chemotherapy 
 
 Yes 15 * 
No 20 † 
Resectable EHD present 
 
 Yes 1 
No 36 
Serum biomarkers – median (IQR) 
 
 HOMA-IR 1.0 (0.6 – 1.3) 
 Adiponectin (mg/l) 12.4 (10.0 – 16.2) 
 Leptin (ug/l) 14.8 (9.1 – 25.2) 
 Fetuin A (g/l) 0.46 (0.40 – 0.56) 
   
* 6 received pre-operative liver chemotherapy; 9 finished adjuvant bowel chemotherapy <6 months before liver 
resection 
† 15 patients never received chemotherapy; 5 finished adjuvant bowel chemotherapy ≥6 months before 
liver resection 
ASA: American Society of Anesthesiology. BMI: Body Mass Index. CEA: CarcinoEmbryonic Antigen.  
EHD: Extra-hepatic disease.  IQR: inter-quartile range. 
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Table 2 Correlations (Spearman coefficients) of various anthropometric measures, serum markers and intra-hepatic fat (%) 
 BMI WC SAT Vol VAT Vol HOMA-IR Leptin Adiponectin Fetuin 
WC 0.79*        
SAT Vol 0.75* 0.75*       
VAT Vol 0.65* 0.76* 0.53*      
HOMA-IR 0.56* 0.57* 0.39* 0.38*     
Leptin 0.46* 0.18 0.46* 0.08 0.38*    
Adiponectin -0.17 -0.33* -0.10 -0.37* -0.13 0.00   
Fetuin-A 0.13 -0.03 -0.01 0.06 -0.14 0.16 -0.02  
Intra-hepatic fat 
% 
0.28 0.29 0.25 0.36* 0.29 0.14 -0.33 0.15 
 
*p value < 0.01 
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Table 3 Multivariable linear regression model with D-IHF as the dependent variable 
 
Variable 
 
Beta coefficient 
 
95% CIs 
 
P value 
Model fit 
(AIC) 
Preliminary model (after factor cluster analyses) 
   3.820 
Age (per year increase) 0.0343 -0.0221, 0.9074 0.222  
Gender (men versus women) 1.5857 -0.6118, 3.227 0.058  
Alcohol (≥ 10 units/week versus < 10 units/week) 1.5573 0.1677, 2.9469 0.030  
BMI (per 1 kg/m2 increase) 0.0330 -0.2153, 0.2812 0.787  
Measured WC (per 1 cm increase) -0.0032 -0.1215, 0.1151 0.956  
CT-derived WC (per 1 cm increase) -0.0085 -0.1258, 0.1088 0.882  
VAT volume (per 1 cm3 increase) 0.0003 -0.0009, 0.002 0.575  
HOMA-IR (per doubling) 2.0215 0.7491, 5.4551 0.157  
Adiponectin (per doubling) 0.2121 0.0566, 0.7940 0.023  
     
Final model 
   3.623 
Age (per year increase) 0.0339 -0.0173, 0.0850 0.186  
Gender (male versus female) 1.3688 0.0879, 2.650 0.037  
Alcohol (≥ 10 units/week versus < 10 units/week) 1.7596 0.5559, 2.9633 0.006  
HOMA-IR (per doubling) 2.4137 1.0934, 5.3134 0.030  
Adiponectin (per doubling) 0.1970 0.0582, 0.6672 0.011  
     
AIC: Akaike Information Criterion 
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SUPPLEMENTARY MATERIAL 
Digital Histology Quantification of Intra-hepatic Fat in Patients undergoing Liver 
Resection  
 
Parkin et al. 
SUPPLEMENTAL METHODS 
Validity of the 7-slide technique 
Li et al.1 examined 7 histological sections and scored intra-hepatic fat content as the mean 
of these 7 scores. Based on this technique, and for pragmatic reasons, we examined 7 
slides as well. To test the validity of this technique, in one patient with an average amount of 
fat on 7 slides, I examined 43 images. The mean digitally quantified histological score from 
the 43 was 4.30. This was taken as the true mean. I then randomly sampled this data with 
replacement as samples n = 40, n = 35, n = 30 ……….. n = 4 (Figure S1). Each re-sampling 
was performed 500 times for each theoretical number of slides. For each number of slides, a 
distribution (n = 500) of means was derived, which itself had a mean and 5th and 95th 
percentiles. If we set the limits of acceptable variation between +25% and -25% of the true 
mean (i.e. 3.23 and 5.38) the probability that the derived mean lies outside the pre-set limits 
is high if we examined less than 7 slides. The 7-slide technique was therefore accepted as 
‘fit for purpose’. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1 The distribution (n = 500) of means was derived, which has a mean (thick black
line) and 5th and 95th percentiles (shaded area). If the limits of acceptable variation are
between +25% and -25% of the true mean (3.23 to 5.38, red dashed lines), the probability
that the derived mean lies outside these limits is high if we examine less than 7 slides.
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To assess the reproducibility of the Adobe 7-slide technique, the variability in fat 
quantification according to (i) the same rater at different time points (intra-rater variability) 
and by (ii) different raters (inter-rater variability) was assessed using the concordance 
correlation coefficient (Stata command: concord). Histology measurements were repeated 
at separate sittings, for the first 19 patients to assess intra-rater variability. A second rater 
independently analysed histology 7 slides for every fifth patient to assess inter-rater 
variability for the technique. Both correlations were excellent: the concordance correlation 
coefficient for intra-rater variability was 0.98; for inter-rater variability it was 0.97. 
 
Intra- and inter-rater variability 
Each CT parameter was measured twice at separate sittings to explore intra-rater variability. 
A radiologist (Dr Andrew Plumb) performed measurements independently to explore inter-
rater variability. The concordance correlation coefficient was used for the statistical analysis. 
Results of inter- and intra-rater variability for the 37 patients ultimately recruited in to the 
OSCAR study is shown in Table S1. There was good to excellent agreement for all 
measurements. In general, WC and SAT and VAT volumes showed the strongest 
correlations, and inter-rater variability was greater than intra-rater variability.  
 
Table S1 Inter- and intra-rater variability for CT fat measurements 
Measurement Inter-rater variability 
(CCC, rho) 
Intra-rater variability 
(CCC, rho) 
   
WC  0.991 0.997 
SAT thickness  0.922 0.978 
VAT thickness  0.862 0.895 
SAT area  0.906 0.925 
VAT area  0.956 0.975 
SAT volume  0.965 0.991 
VAT volume  0.971 0.986 
   
CCC: concordance coefficient 
 
 
 
Scatter plots to show inter-rater variability and levels of agreement for the three different 
VAT measurements (thickness, area and volume) are shown in Figure S2.  
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Figure S2:Inter-rater variability and levels of agreement for the three CT measures of 
visceral fat – thickness, area and volume 
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Figure S3: Factor-cluster approach to multivariate linear regression model
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